Floatz logo

186 assets in Her2-Receptor Negative Breast Cancer

Therapeutic assets addressing Her2-Receptor Negative Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
nkt3964
Her2-Receptor Negative Breast Cancer
NiKang Therapeutics, Inc.P1CC (43)
Rgt-490
Her2-Receptor Negative Breast Cancer
Regor Pharmaceuticals Inc.P1CC (43)
Rimiducid
Her2-Receptor Negative Breast Cancer
Memorial Sloan Kettering Cancer CenterP1CC (43)
Sigvotatug Vedotin
Her2-Receptor Negative Breast Cancer
Seagen, a wholly owned subsidiary of PfizerP1CC (43)
Vistusertib
Her2-Receptor Negative Breast Cancer
M.D. Anderson Cancer CenterP1CC (43)
Mirdametinib
Her2-Receptor Negative Breast Cancer
Memorial Sloan Kettering Cancer CenterP1/2CC (42)
Adg 106
Her2-Receptor Negative Breast Cancer
National University Hospital, SingaporeP1/2CC (41)
Nuv-1511
Her2-Receptor Negative Breast Cancer
Nuvation Bio Inc.P1/2CC (41)
Oxodotreotide
Her2-Receptor Negative Breast Cancer
RayzeBio, Inc.P1/2CC (41)
Polo-Like Kinase 1 Inhibitor Nms-1286937
Her2-Receptor Negative Breast Cancer
Antonio Giordano, MDP1/2CC (41)
Axitinib
Her2-Receptor Negative Breast Cancer
Lynkcell EuropeP1CC (40)
Bgb-43395
Her2-Receptor Negative Breast Cancer
BeOne MedicinesP1CC (40)
BMS986310
Her2-Receptor Negative Breast Cancer
Ono Pharmaceutical Co., Ltd.P1CC (40)
Rly-5836
Her2-Receptor Negative Breast Cancer
Relay Therapeutics, Inc.P1CC (40)
Amcenestrant
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2C (39)
Simvastatin
Her2-Receptor Negative Breast Cancer
Emory UniversityEarly P1C (39)
Technetium Tc 99M Sestamibi
Her2-Receptor Negative Breast Cancer
M.D. Anderson Cancer CenterEarly P1C (39)
Aquocobalamin
Her2-Receptor Negative Breast Cancer
General Oncology, Inc.P1C (37)
Atirmociclib
Her2-Receptor Negative Breast Cancer
Olema Pharmaceuticals, Inc.P1C (37)
Azenosertib
Her2-Receptor Negative Breast Cancer
Filipa Lynce, MDP1C (37)
Bgb-21447
Her2-Receptor Negative Breast Cancer
BeOne MedicinesP1C (37)
Camustine
Her2-Receptor Negative Breast Cancer
General Oncology, Inc.P1C (37)
CD47/SIRPA-BLOCKING AGENT ALX148
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP1C (37)
Cdx 1140
Her2-Receptor Negative Breast Cancer
University of Texas Southwestern Medical CenterP1C (37)
Cirtociclib
Her2-Receptor Negative Breast Cancer
Blueprint Medicines CorporationP1C (37)
dr-0202
Her2-Receptor Negative Breast Cancer
Dren BioP1C (37)
Fam-Trastuzumab Deruxtecan-Nxki
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP1C (37)
her2 - primed dendritic cells
Her2-Receptor Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research InstituteP1C (37)
her3 - primed dendritic cells
Her2-Receptor Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research InstituteP1C (37)
Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer
Her2-Receptor Negative Breast Cancer
Dana-Farber Cancer InstituteP1C (37)
Melphalan
Her2-Receptor Negative Breast Cancer
General Oncology, Inc.P1C (37)
Naptumomab Estafenatox
Her2-Receptor Negative Breast Cancer
NeoTX Therapeutics Ltd.P1C (37)
Obinutuzumab
Her2-Receptor Negative Breast Cancer
NeoTX Therapeutics Ltd.P1C (37)
Jskn016
Her2-Receptor Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., LtdP1/2NR ()
Rezatapopt
Her2-Receptor Negative Breast Cancer
PMV Pharmaceuticals, IncP1/2NR ()
Tolinapant
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P1NR ()
Showing 151 to 186 of 186 assets
PreviousPage 4 of 4Next